Genetic Carbohydrate Maldigestion as a Model to Study Food Hypersensitivity
Key facts
- Who runs it
- Nottingham University Hospitals NHS Trust
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 2,000 people, planned
- Started
- 23 Jul 2024
- Ended
- 31 Mar 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Stool and saliva sample collection
- Questionnaire completion
- Record updated
- 19 December 2025
Who can take part
- Age
- 5 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Patients age between 5 and 70 years of age
- Patients with IBS-D or IBS-M as defined by the Rome III criteria
- Previous negative endoscopy with biopsies excluding IBD or microscopic colitis in patients above 50 years old
- Negative relevant additional screening or consultation whenever appropriate
- Ability to conform to the study protocol
- Between 5 and 70 years of age
- Absence of Rome III IBS criteria
Who cannot take part
- Patients with concurrent organic gastrointestinal disease (inflammatory bowel disease, celiac disease, cancer), or a major disease such as diabetes, uncontrolled thyroid disease
- Concurrent major confounding condition, e.g. alcohol or substance abuse in the last 2 years (clinician's judgement)
- Patients with any condition which, in the opinion of the investigator, makes the patient unsuitable for participation in the study
- Patients with a history of bowel surgery (not appendectomy or cholecystectomy)
- Person with any condition which, in the opinion of the investigator, makes them unsuitable for participation in the study
- Person presenting with a functional or organic GI disorder
- Person presenting with underlying disease that may involve the GI tract (e.g. Parkinson's disease) or be associated with GI symptoms (e.g. anorexia nervosa, major depression)
- Patients with IBS-C or IBS-U according to Rome III criteria
- Patients on opioids
- Blood relatives of the participating IBS patient are not allowed to participate
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Irritable bowel syndrome (IBS) affects one in seven people with gastrointestinal (GI) symptoms. IBS strongly impacts quality of life, is a leading cause of work absenteeism, and consumes 0.5% of the healthcare annual budget. It manifests in women more than men with symptoms including abdominal pain, bloating, constipation (IBS-C), diarrhoea (IBS-D), and mixed presentations (IBS-M) (1). The development of therapeutic options is hampered by the poor understanding of the underlying cause of symptoms.
Read full original descriptionShow less
Many patients find that certain foods (particularly carbohydrates) trigger their symptoms, and avoiding such foods has been shown effective in IBS, like in the low-FODMAP (fermentable oligo-, di-, mono-saccharides and polyols) exclusion diet.
This has suggested that the food-symptom relation may involve malabsorption of carbohydrates due to inefficient digestion. However only a percentage of patients respond to this diet. Recently it has been reported that a subset of IBS carries hypomorphic (defective) gene variant of the sucrase isomaltase (SI), the enzyme that normally digests carbohydrates, sucrose and starch. This carbohydrate maldigestion (the breakdown of complex carbohydrates by a person's small bowel enzymes) is characterized by diarrhoea, abdominal pain and bloating, which are also features of IBS. This possibly occurs via accumulation of undigested carbohydrates in the large bowel, where they cause symptoms due to gas production following bacterial fermentation. Similar mechanisms may be acting at the level of other enzymes involved in the digestion, breakdown and absorption of carbohydrates (carb digestion genes -CDGs). Aim of the study is to study the prevalence of this genetic alteration in a large number of IBS patients as compared to asymptomatic controls.
The 2 groups in the trial
- IBS Patient
IBS patient with diarrhoea or alternating bowel habit
Treatment: Stool and saliva sample collection and Questionnaire completion
- Healthy subject
Participants without IBS
Treatment: Stool and saliva sample collection and Questionnaire completion
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Genetic Carbohydrate Maldigestion as a Model to Study Food Hypersensitivity Mechanism and Guide Personalised Treatment Using a Non-invasive Multiparametric Test (Work Package 1)
- Record updated
- 19 December 2025